SCHEDULE 13G 0001595855 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 02/19/2026 0001661998 Q32 Bio Inc. 746964105 830 Winter Street, Waltham MA 02451 Rule 13d-1(c) Opaleye Management Inc. MA 0.00 1256228.00 0.00 1256228.00 1256228.00 N 8.65 IA CO Opaleye, L.P. MA 0.00 1256228.00 0.00 1256228.00 1256228.00 N 8.65 PN Based on 14,524,726 Common Shares outstanding as of 02/17/2026 as reported by Q32 Bio Inc. on 02/17/2026, in its 424B5 Prospectus. James Silverman X1 0.00 1256228.00 0.00 1256228.00 1256228.00 N 8.65 IN Q32 Bio Inc. 830 Winter Street, Waltham, MA 02451 Opaleye Management Inc. Opaleye, L.P. James Silverman This statement is filed by (i) Opaleye Management Inc. (the "Adviser"), (ii) Opaleye, L.P. (the "Fund") and (iii) James Silverman with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of Q32 Bio Inc. (the "Issuer") directly held by the Fund. The Adviser serves as investment adviser to the Fund. Mr. Silverman exercises control over the Adviser. The filing of this statement should not be construed as an admission that any of the foregoing persons is, for the purposes of Section 13 of the Securities Exchange Act, the beneficial owner of the shares reported herein. One Boston Place, 26th Floor, Boston, MA 02108 Opaleye Management Inc. - Massachusetts Opaleye, L.P. - Massachusetts James Silverman - United States N IA 1,256,228.00 8.65 % 0 1,256,228.00 0 1,256,228.00 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement by and among the reporting persons Opaleye Management Inc. /s/ James Silverman 02/20/2026 Opaleye, L.P. /s/ James Silverman 02/20/2026 James Silverman /s/ James Silverman 02/20/2026